Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042

Table 1 Patient’s characteristics

Patient #	Subtype¹	Stage at baseline	Biopsies²
10	FCBCL	NA	Baseline, C1
13	CD30⁺ ALCL	IIB	Baseline, C1
16	CD30⁺ ALCL	IIA	Baseline, C1, C2
17	GSS	IB	Baseline, C1, C2, C3, C4, C6, C9, C10
18	MF	IIB	Baseline, C1, C2
20	CD30⁺ ALCL	IIB	Baseline, C1
24	Pleomorphic CTCL	IB	Baseline, C1, C4, Last Visit
25	MF	IB	Baseline, C1, C4, Last Visit
27	MF	IIB	Baseline, C1
29	MF	IB	Baseline, C1, Last Visit
30	MF	IB	Baseline, C1, C4
31	MF	IIB	Baseline, C1, C4
33	DLBCL	T3a	Baseline, C1
34	MF	IB	Baseline, C1, Last Visit
35	MZBCL	T3b	Baseline, C1
36	MF	IB	Baseline, C1, C4
37	CD30⁺ ALCL	IIB	Baseline, C2
38	MF	IB	Baseline, C1, C4, Last Visit
39	MF	IIB	Baseline, C1, C3

Summary of relevant information for each patient analysed (patient number, histology subtype, stage at baseline and time of biopsies sampling).
NA not applicable.
¹Pathology subtypes: ALCL indicates anaplastic large cell lymphoma, MF Mycosis fungoides, CBCL cutaneous B-cell lymphoma, DLBCL diffuse large B-cell lymphoma, FCBCL follicle center B-cell lymphoma, MZBCL marginal zone B-cell lymphoma, Pleomorphic CTCL Pleomorphic cutaneous T-cell lymphoma, LyP lymphomatoid papulosis, GSS granulomatous slack skin.
²Cx: C:Cycle. x: cycle number at which the examined biopsies were sampled. See Material and Methods for Cycle definition.

ISSN: 1479-5876